[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors

August 2013 | 13 pages | ID: CEB848109E1EN
La Merie Publishing

US$ 132.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The present Competitive Intelligence report about Bruton’s Tyrosine Kinase (BTK) Inhibitorsprovides a competitor evaluation in the field of small molecule-based inhibitors of Bruton’s Tyrosine Kinase (BTK) for the treatment of B-cell related hematologic malign ancies and autoimmune diseases as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of small molecule Bruton’s Tyrosine Kinase (BTK) inhibitors in oncology and inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of BTK inhibitors. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About theCompetitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • BTK Inhibitors in Oncology
  • BTK Inhibitors in Inflammatory and Autoimmune Diseases
  • Corporate BTK Inhibitor R&D Pipelines


More Publications